Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer | Zendy

Ray Hachem | Zendy; Ruth Reitzel | Zendy; Kenneth V. I. Rolston | Zendy; AnneMarie Chaftari | Zendy; Issam Raad | Zendy

Open Access

Antimicrobial Activities of Ceftazidime-Avibactam and Comparator Agents against Clinical Bacteria Isolated from Patients with Cancer

Author(s) -

Ray Hachem,

Ruth Reitzel,

Kenneth V. I. Rolston,

AnneMarie Chaftari,

Issam Raad

Publication year - 2017

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.02106-16

Subject(s) - ceftazidime/avibactam , cefepime , ceftazidime , broth microdilution , microbiology and biotechnology , meropenem , pseudomonas aeruginosa , tazobactam , piperacillin , antimicrobial , avibactam , medicine , biology , bacteria , antibiotics , minimum inhibitory concentration , antibiotic resistance , genetics

A total of 521 unique clinical isolates from cancer patients with primarily (>90%) bloodstream infections were tested for susceptibility to ceftazidime-avibactam and comparators using broth microdilution methods. Ceftazidime-avibactam inhibited 97.8% of allEnterobacteriaceae (n = 321) at the susceptibility breakpoint of ≤8/4 μg/ml (there were 7 nonsusceptible strains). It was also active againstPseudomonas aeruginosa (91.7% isolates susceptible,n = 121), including many isolates not susceptible to meropenem, cefepime, ceftazidime, piperacillin-tazobactam, or other comparators.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research